| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Pamela Doty | |
| William Byrnes | |||
| David Hebert | |||
| Francois-Xavier Mathy | |||
| James Zackheim | |||
| Kelly Simontacchi | |||
| P2860 | cites work | Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers | Q43587289 |
| Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial | Q46138712 | ||
| The novel antiepileptic drug lacosamide blocks behavioral and brain metabolic manifestations of seizure activity in the 6 Hz psychomotor seizure model | Q46743536 | ||
| The social and economic consequences of epilepsy: a controlled national study | Q48319363 | ||
| Epilepsy | Q55899118 | ||
| Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: A pharmacodynamic interaction? | Q58449801 | ||
| Tolerability, pharmacokinetics, and bioequivalence of the tablet and syrup formulations of lacosamide in plasma, saliva, and urine: saliva as a surrogate of pharmacokinetics in the central compartment. | Q64984039 | ||
| Epilepsy after the first drug fails: substitution or add-on? | Q73085681 | ||
| No pharmacokinetic interaction between lacosamide and valproic acid in healthy volunteers | Q82918294 | ||
| Rational polytherapy with lacosamide in clinical practice: results of a Spanish cohort analysis RELACOVA | Q83523024 | ||
| Add-on lacosamide: a retrospective study on the relationship between serum concentration, dosage, and adverse events | Q85025187 | ||
| The adverse event profile of lacosamide: a systematic review and meta-analysis of randomized controlled trials | Q27026195 | ||
| Safety and tolerability of adjunctive lacosamide intravenous loading dose in lacosamide-naive patients with partial-onset seizures | Q30455664 | ||
| Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society | Q33202108 | ||
| ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes | Q33252737 | ||
| A Pooled Analysis of Lacosamide Clinical Trial Data Grouped by Mechanism of Action of Concomitant Antiepileptic Drugs | Q33751484 | ||
| In silico docking and electrophysiological characterization of lacosamide binding sites on collapsin response mediator protein-2 identifies a pocket important in modulating sodium channel slow inactivation | Q34055749 | ||
| Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy | Q34618958 | ||
| Lacosamide: a review of preclinical properties. | Q34623155 | ||
| Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures | Q34652020 | ||
| Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures | Q34691856 | ||
| The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. | Q34701722 | ||
| Disparities in NIH funding for epilepsy research | Q35691548 | ||
| Combination therapy in epilepsy: when and what to use. | Q36622991 | ||
| Quality-of-life trajectories in epilepsy: a review of the literature | Q37044834 | ||
| Antiepileptic drug therapy: does mechanism of action matter? | Q37901704 | ||
| Adjunctive lacosamide in clinical practice: sodium blockade with a difference? | Q37926255 | ||
| Sodium channels and the neurobiology of epilepsy | Q38035905 | ||
| Drug binding assays do not reveal specific binding of lacosamide to collapsin response mediator protein 2 (CRMP-2). | Q39336259 | ||
| Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial | Q42638125 | ||
| Intravenous lacosamide as short-term replacement for oral lacosamide in partial-onset seizures | Q42644393 | ||
| Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials | Q42797086 | ||
| Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial | Q43173503 | ||
| No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers | Q43258641 | ||
| P275 | copyright license | Creative Commons Attribution 2.5 Generic | Q18810333 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | carboxylic acid | Q134856 |
| amides | Q188777 | ||
| anticonvulsant agent | Q576618 | ||
| focal epilepsy | Q7140388 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 56-68 | |
| P577 | publication date | 2013-07-01 | |
| P1433 | published in | Annals of the New York Academy of Sciences | Q2431664 |
| P1476 | title | Development of lacosamide for the treatment of partial-onset seizures | |
| P478 | volume | 1291 |
| Q33167023 | A long-term noninterventional safety study of adjunctive lacosamide therapy in patients with epilepsy and uncontrolled partial-onset seizures |
| Q40651545 | Acute or chronic use of lacosamide does not alter its distribution between serum and cerebrospinal fluid |
| Q51744039 | Adjunctive Eslicarbazepine Acetate in Pediatric Patients with Focal Epilepsy: A Systematic Review and Meta-Analysis. |
| Q38244248 | Advances in epilepsy treatment: lacosamide pharmacokinetic profile |
| Q38468591 | Clinical pharmacokinetic and pharmacodynamic profile of lacosamide |
| Q50599628 | Cognitive effects of lacosamide as adjunctive therapy in refractory epilepsy. |
| Q39989931 | Efficacy and Tolerability of Lacosamide in the Treatment of Children With Refractory Generalized Epilepsy |
| Q50883978 | Female anorgasmia induced by lacosamide: Rare or neglected side effect? |
| Q30399934 | Lacosamide in status epilepticus: Systematic review of current evidence. |
| Q49053027 | Lacosamide inhibits calcitonin gene-related peptide production and release at trigeminal level in the rat. |
| Q50201563 | Lacosamide treatment of childhood refractory focal epilepsy: the first reported side effect in paediatric patients |
| Q52696502 | Lacosamide-Induced Recurrent Ventricular Tachycardia in the Acute Care Setting. |
| Q88766207 | Lacosamide: A Review in Focal-Onset Seizures in Patients with Epilepsy |
| Q38160816 | Lacosamide: a review of its use as adjunctive therapy in the management of partial-onset seizures |
| Q64120050 | Preparation, Characterization, and Stability Evaluation of Taste-Masking Lacosamide Microparticles |
| Q87189649 | Sexual dysfunction induced by lacosamide: An underreported side effect? |
| Q47419334 | The effects of lacosamide on cognition, quality-of-life measures, and quality of life in patients with refractory partial epilepsy |
| Q37722778 | The efficacy of lacosamide as monotherapy and adjunctive therapy in focal epilepsy and its use in status epilepticus: clinical trial evidence and experience |
| Q51823925 | Treatment with lacosamide impedes generalized seizures in a rodent model of cortical dysplasia. |
Search more.